Research Use Only • Third-Party Tested • Batch Verified
$129
Retatrutide (LY3437943) is a long-acting triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. This modified multi-agonist peptide is currently being investigated for its effects on energy balance, glucose metabolism, lipid utilization, and multi-pathway metabolic signaling in research settings only.
Independent analytical testing performed on supported batches.
Documentation linked to production and verification records.
Verification resources available for supported products and batches.
Synonym: LY3437943
CAS Number: 2381089-83-2
Molecular Formula: C₂₂₇H₃₅₄N₄₈O₆₉
Molecular Weight: ~4731.33 g/mol
Structure: Modified multi-agonist peptide with lipidation for extended half-life
Retatrutide is a synthetic, long-acting peptide engineered as a triple receptor agonist targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents a unimolecular approach to simultaneously modulate multiple metabolic signaling pathways involved in energy balance, glucose homeostasis, and lipid metabolism.
The peptide incorporates structural modifications, including fatty acid conjugation, to enhance albumin binding and prolong systemic exposure.
Retatrutide exerts its effects through concurrent activation of three incretin-related receptors:
GLP-1 Receptor Agonism
Enhances glucose-dependent insulin secretion
Slows gastric emptying
Reduces food intake via central signaling pathways
GIP Receptor Agonism
Modulates insulin secretion in a glucose-dependent manner
May influence adipocyte function and nutrient partitioning
Glucagon Receptor Agonism
Increases energy expenditure
Promotes lipolysis and hepatic glucose output
Contributes to metabolic rate elevation
The combined agonism results in a coordinated effect on appetite regulation, energy expenditure, and metabolic substrate utilization.
Extended half-life via lipidation and albumin binding
Designed for once-weekly administration in research settings
Reduced renal clearance due to increased molecular size and binding affinity
Retatrutide is a modified peptide backbone derived from incretin hormone analogs, incorporating:
Amino acid substitutions for receptor selectivity and stability
Resistance to enzymatic degradation (e.g., DPP-4)
A C18 fatty diacid side chain enabling reversible albumin binding
Retatrutide is currently under investigation in preclinical and clinical research for its effects on:
Energy balance and weight regulation
Glucose metabolism and insulin sensitivity
Lipid metabolism and hepatic fat accumulation
Multi-receptor incretin pathway interactions
It is of particular interest in studies evaluating combined incretin and glucagon receptor signaling as a strategy for metabolic modulation.
Typically supplied as a lyophilized powder
Requires reconstitution with a sterile solvent prior to use
Should be stored at low temperatures (commonly -20°C or below) for long-term stability
Avoid repeated freeze-thaw cycles
This material is intended for laboratory research use only and is not approved for human or veterinary applications.
Every batch undergoes independent third-party analytical testing for purity, identity, and consistency. Relevant documentation is maintained to support verification and traceability.
Yes. Analytical documentation is maintained for supported products and batches. Verification resources are available to help researchers review relevant testing information.
Each production batch is assigned documentation that links materials to associated testing records and verification resources, helping maintain consistency and transparency.
Yes. Analytical documentation is maintained for supported products and batches. Verification resources are available to help researchers review relevant testing information.
Each production batch is assigned documentation that links materials to associated testing records and verification resources, helping maintain consistency and transparency.
